Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness

Journal of Pediatric Rehabilitation Medicine

Volumn 7, Issue 3, 2014, Pages 255-265

  Jones, Harrison N ^a   Crisp, Kelly D ^a   Moss, Tronda ^a   Strollo, Katherine ^a   Robey, Randy ^b   Sank, Jeffrey ^a   Canfield, Michelle ^a   Case, Laura E ^c   Mahler, Leslie ^d   Kravitz, Richard M ^a   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

breathing exercises; Glycogen storage disease type II; muscle; neuromuscular diseases; rehabilitation; skeletal

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

6 MINUTE WALK TEST; ARTICLE; BREATHING MUSCLE; CASE REPORT; CHILD; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LONG TERM CARE; MALE; MAXIMUM EXPIRATORY PRESSURE; MAXIMUM INSPIRATORY PRESSURE; MUSCLE STRENGTH; MUSCLE TRAINING; MUSCLE WEAKNESS; PEAK COUGH FLOW; PRESCHOOL CHILD; RESPIRATORY MUSCLE TRAINING; RESPIRATORY MUSCLE WEAKNESS; RESPIRATORY TRACT PARAMETERS; SPIROMETRY; SURVIVOR; AIRWAY RESISTANCE; BREATHING EXERCISE; EXHALATION; GLYCOGEN STORAGE DISEASE TYPE II; INHALATION; LUNG; MUSCLE CONTRACTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

AIRWAY RESISTANCE; BREATHING EXERCISES; CHILD; EXHALATION; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INHALATION; LUNG; MUSCLE CONTRACTION; RESPIRATORY MUSCLES;

EID: 84907671461     PISSN: 18745393     EISSN: 18758894     Source Type: Journal    
DOI: 10.3233/PRM-140294     Document Type: Article

References (49)

1. Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998 Aug 27;79(1): 69-72. PubMed PMID: 9738873
2. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004 May;144(5 Suppl):S35-43. PubMed PMID: 15126982
3. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006 May;148(5):671-6. PubMed PMID: 16737883. eng
4. van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003 Aug;112(2):332-40. PubMed PMID: 12897283
5. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. Recombinant human acid alphaglucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001 Mar-Apr;3(2):132-8. PubMed PMID: 11286229. eng
6. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006 Jul;149(1):89-97. PubMed PMID: 16860134. Pubmed Central PMCID: 2692727
7. Klinge L, Straub V, Neudorf U, Voit T. Enzyme replacement therapy in classical infantile pompe disease: results of a tenmonth follow-up study. Neuropediatrics. 2005 Feb;36(1):6-11. PubMed PMID: 15776317
8. Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Gorlinger K, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord. 2005 Jan;15(1):24-31. PubMed PMID: 15639117
9. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009 Mar;11(3):210-9. PubMed PMID: 19287243
10. Rossi M, Parenti G, Della Casa R, Romano A, Mansi G, Agovino T, et al. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells. J Child Neurol. 2007 May;22(5):565-73. PubMed PMID: 17690063
11. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000 Jul 29;356(9227):397-8. PubMed PMID: 10972374
12. Van den Hout JM, Reuser AJ, de Klerk JB, ArtsWF, Smeitink JA, Van der Ploeg AT. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis. 2001 Apr;24(2):266-74. PubMed PMID: 11405345
13. Rigter T, Weinreich SS, van El CG, de Vries JM, van Gelder CM, Gungor D, et al. Severely impaired health status at diagnosis of Pompe disease: a cross-sectional analysis to explore the potential utility of neonatal screening. Mol Genet Metab. 2012 Nov;107(3):448-55. PubMed PMID: 23040796
14. Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009 Sep;66(3):329-35. PubMed PMID: 19542901. Pubmed Central PMCID: 3129995
15. Battaglia E, Fulgenzi A, Ferrero ME. Rationale of the combined use of inspiratory and expiratory devices in improving maximal inspiratory pressure and maximal expiratory pressure of patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2009 Jun;90(6):913-8. PubMed PMID: 19480865
16. Forbes S, Game A, Syrotuik D, Jones R, Bell GJ. The effect of inspiratory and expiratory respiratory muscle training in rowers. Res Sports Med. 2011 Oct;19(4):217-30. PubMed PMID: 21988265
17. Jones HN, Moss T, Edwards L, Kishnani PS. Increased inspiratory and expiratory muscle strength following respiratory muscle strength training (RMST) in two patients with late-onset Pompe disease. Mol Genet Metab. 2011 Nov; 104(3):417-20. PubMed PMID: 21641843
18. Lotters F, van Tol B, Kwakkel G, Gosselink R. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J. 2002 Sep;20(3):570-6. PubMed PMID: 12358330
19. Weiner P, Gross D, Meiner Z, Ganem R, Weiner M, Zamir D, et al. Respiratory muscle training in patients with moderate to severe myasthenia gravis. Can J Neurol Sci. 1998 Aug; 25(3):236-41. PubMed PMID: 9706726
20. Backman CL, Harris SR, Chisholm JA, Monette AD. Singlesubject research in rehabilitation: A review of studies using AB, withdrawal, multiple baseline, and alternating treatments designs. Arch Phys Med Rehabil. 1997 Oct;78(10):1145-53. PubMed PMID: 9339167
21. Janosky JE, Leininger SL, HoergerMP, Libkuman TM. Single Subject Designs in Biomedicine New York: Springer; 2009. 124 p.
22. Robey RR, Wambaugh J. Single-subject versus randomized group design. ASHA. 1999 Nov-Dec;41(6):14-5. PubMed PMID: 10570545
23. Prigent H, Orlikowski D, Laforet P, Letilly N, Falaize L, Pellegrini N, et al. Supine volume drop and diaphragmatic function in adults with Pompe disease. Eur Respir J. 2012 Jun; 39(6):1545-6. PubMed PMID: 22654013
24. Busk P, Serlin, RC. Meta-analysis for single-case research In: Kratochwill T, & Levin, JR, editor. Single-Case Research De sign and Analysis: New Directions for Psychology and Education. Hillsdale, NJ: Lawrence Erlbaum Associates; 1992
25. American Thoracic Society/European Respiratory S. ATS/ ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002 Aug 15;166(4):518-624. PubMed PMID: 12186831
26. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. PubMed PMID: 12091180. Epub 2002/07/02. eng
27. Heinzmann-Filho JP, Vasconcellos Vidal PC, Herbert Jones M, Fagundes Donadio MV. Normal values for respiratory muscle strength in healthy preschoolers and school children Respir Med. 2012 August;106:1639-46. Epub 10 September 2012
28. Wilson SH, Cooke NT, Edwards RH, Spiro SG. Predicted normal values for maximal respiratory pressures in caucasian adults and children. Thorax. 1984 Jul;39(7):535-8. PubMed PMID: 6463933. Pubmed Central PMCID: Pmc459855. Epub 1984/07/01.eng
29. Wanke T, Toifl K, Merkle M, Formanek D, Lahrmann H, Zwick H. Inspiratory muscle training in patients with Duchenne muscular dystrophy. Chest. 1994 Feb;105(2):475-82. PubMed PMID: 8306750
30. KoesslerW,Wanke T,Winkler G, Nader A, Toifl K, Kurz H, et al. 2 Years' experience with inspiratory muscle training in patients with neuromuscular disorders. Chest. 2001 Sep;120(3): 765-9. PubMed PMID: 11555507
31. Gozal D, Thiriet P. Respiratory muscle training in neuromuscular disease: long-term effects on strength and load perception. Med Sci Sports Exerc. 1999 Nov;31(11):1522-7. Pub Med PMID: 10589852
32. McCool FD, Tzelepis GE. Inspiratory muscle training in the patient with neuromuscular disease. Phys Ther. 1995 Nov; 75(11):1006-14. PubMed PMID: 7480122
33. Mujika I, Padilla S. Detraining: Loss of training-induced physiological and performance adaptations. Part I: short term insufficient training stimulus. Sports Med. 2000 Aug;30(2): 79-87. PubMed PMID: 10966148
34. Baker S, Davenport P, Sapienza C. Examination of strength training and detraining effects in expiratory muscles. J Speech Lang Hear Res. 2005 Dec;48(6):1325-33. PubMed PMID: 16478374
35. Chiara T, Martin AD, Davenport PW, Bolser DC. Expiratory muscle strength training in persons with multiple sclerosis having mild to moderate disability: Effect on maximal expiratory pressure, pulmonary function, and maximal voluntary cough. Arch Phys Med Rehabil. 2006 Apr;87(4):468- 73. PubMed PMID: 16571384. Pubmed Central PMCID: 3121162
36. Chiara T, Martin D, Sapienza C. Expiratory muscle strength training: speech production outcomes in patients with multiple sclerosis. Neurorehabil Neural Repair. 2007 May-Jun; 21(3):239-49. PubMed PMID: 17351085
37. Romer LM, McConnell AK. Specificity and reversibility of inspiratory muscle training. Med Sci Sports Exerc. 2003 Feb; 35(2):237-44. PubMed PMID: 12569211
38. Saleem AF, Sapienza CM, Okun MS. Respiratory muscle strength training: treatment and response duration in a patient with early idiopathic Parkinson's disease. NeuroRehabilitation. 2005;20(4):323-33. PubMed PMID: 16403998
39. Sapienza CM. Respiratory muscle strength training applications. Curr Opin Otolaryngol Head Neck Surg. 2008 Jun; 16(3):216-20. PubMed PMID: 18475074
40. Warren SF, Fey ME, Yoder PJ. Differential treatment intensity research: A missing link to creating optimally effective communication interventions. Mental retardation and developmental disabilities research reviews. 2007;13(1):70-7. PubMed PMID: 17326112
41. Topin N, Matecki S, Le Bris S, Rivier F, Echenne B, Prefaut C, et al. Dose-dependent effect of individualized respiratory muscle training in children with Duchenne muscular dystrophy. Neuromuscul Disord. 2002 Aug;12(6):576-83. PubMed PMID: 12117483
42. Kleim JA, Jones TA. Principles of experience-dependent neural plasticity: implications for rehabilitation after brain damage. J Speech Lang Hear Res. 2008 Feb;51(1):S225-39. Pub Med PMID: 18230848
43. Dayan E, Cohen LG. Neuroplasticity subserving motor skill learning. Neuron. 2011 Nov 3;72(3):443-54. PubMed PMID: 22078504. Pubmed Central PMCID: 3217208
44. Rodillo E, Noble-Jamieson CM, Aber V, Heckmatt JZ, Muntoni F, Dubowitz V. Respiratory muscle training in Duchenne muscular dystrophy. Arch Dis Child. 1989 May; 64(5):736-8. PubMed PMID: 2658856. Pubmed Central PMCID: 1792043
45. Smith PE, Coakley JH, Edwards RH. Respiratory muscle training in Duchenne muscular dystrophy. Muscle Nerve. 1988 Jul;11(7):784-5. PubMed PMID: 3405245
46. Vilozni D, Bar-Yishay E, Gur I, Shapira Y, Meyer S, Godfrey S. Computerized respiratory muscle training in children with Duchenne muscular dystrophy. Neuromuscul Disord. 1994 May; 4(3):249-55. PubMed PMID: 7919973
47. Pitts T, Bolser D, Rosenbek J, Troche M, Okun MS, Sapienza C. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. Chest. 2009 May;135(5):1301-8. PubMed PMID: 19029430
48. Raben N, Fukuda T, Gilbert AL, de Jong D, Thurberg BL, Mattaliano RJ, et al. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther. 2005 Jan;11(1):48-56. PubMed PMID: 15585405
49. Wilson JM, Loenneke JP, Jo E,Wilson GJ, Zourdos MC, Kim JS. The effects of endurance, strength, and power training on muscle fiber type shifting. J Strength Cond Res. 2012 Jun; 26(6):1724-9. PubMed PMID: 21912291